Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BioAge Labs, Inc (BIOA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: BIOA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 674.12M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 162965 | Beta - | 52 Weeks Range 3.47 - 26.62 | Updated Date 03/25/2025 |
52 Weeks Range 3.47 - 26.62 | Updated Date 03/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.4 |
Earnings Date
Report Date 2025-03-21 | When - | Estimate - | Actual -0.5894 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 539045726 | Price to Sales(TTM) - |
Enterprise Value 539045726 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 34167200 | Shares Floating 1177831 |
Shares Outstanding 34167200 | Shares Floating 1177831 | ||
Percent Insiders 3.8 | Percent Institutions 32.64 |
Analyst Ratings
Rating 2.33 | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
BioAge Labs, Inc
Company Overview
History and Background
BioAge Labs, Inc. is a biotechnology company focused on developing therapies to treat aging-related diseases. Founded in 2015, it leverages a data-driven approach using human longitudinal data to identify promising drug targets and develop clinical-stage programs.
Core Business Areas
- Drug Discovery and Development: Utilizing a data-driven platform to identify and validate drug targets related to aging.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
- Intellectual Property: Developing and protecting intellectual property related to its drug candidates and technologies.
Leadership and Structure
BioAge Labs is led by Kristen Fortney, PhD (CEO), and has a scientific advisory board comprised of leading researchers in the field of aging. The company structure includes research, development, and clinical operations teams.
Top Products and Market Share
Key Offerings
- BGE-175 (azelaprag): An oral apelin receptor agonist being developed for sarcopenia. Currently in Phase 2 clinical trials. Market share is currently 0 as product is in clinical trial phase. Competitors include companies developing other sarcopenia treatments. Currently, there are no FDA-approved therapeutics in the sarcopenia indication. Companies developing potential treatments include Astellas, Amgen, Regeneron.
- BGE-117: A PI3K inhibitor being developed to enhance immune responses to vaccines in older adults. Currently in Phase 2 clinical trials. Market share is currently 0 as product is in clinical trial phase. Competitors include companies developing vaccine adjuvants and immunomodulatory therapies, such as GSK and Seqirus.
Market Dynamics
Industry Overview
The biopharmaceutical industry focusing on aging-related diseases is rapidly growing due to increasing awareness of the health and economic burdens associated with aging. The market is driven by advancements in understanding the biology of aging and the development of new technologies for drug discovery and development.
Positioning
BioAge Labs is positioned as a leader in the data-driven approach to drug discovery for aging-related diseases, leveraging its human longitudinal data platform to identify novel drug targets and accelerate drug development. They have a competitive advantage through their novel targets and Phase 2 assets.
Total Addressable Market (TAM)
The global market for aging-related diseases is estimated to be in the hundreds of billions of dollars. BioAge Labs, with its focus on sarcopenia and immune aging, targets significant portions of this TAM. Successful development and commercialization of their pipeline could capture a substantial market share.
Upturn SWOT Analysis
Strengths
- Proprietary human longitudinal data platform
- Experienced leadership team
- Clinical-stage assets with promising targets
- Strong scientific advisory board
- Innovative approach to drug discovery
Weaknesses
- High cash burn rate
- Reliance on clinical trial success
- Potential competition from larger pharmaceutical companies
- Limited commercial infrastructure
Opportunities
- Expanding pipeline through new drug discovery
- Strategic partnerships with pharmaceutical companies
- Positive clinical trial results leading to FDA approval
- Increasing investment in aging-related research
- Expansion into new indications within aging biology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from companies with greater resources
- Changes in the healthcare landscape
- Patent challenges
Competitors and Market Share
Key Competitors
- Geroscience companies are typically private and there are not public competitor companies. These include but are not limited to: Calico (GOOGL), Altos Labs
Competitive Landscape
BioAge Labs competes with other biotechnology and pharmaceutical companies developing therapies for aging-related diseases. Its competitive advantages include its data-driven approach and novel drug targets. Disadvantages include its limited resources compared to larger pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been focused on advancing its clinical programs, expanding its data platform, and securing funding through venture capital and strategic partnerships.
Future Projections: Future growth is dependent on clinical trial success, expanding its pipeline, and potential acquisition by a larger pharmaceutical company. Analyst projections are not available due to its private status.
Recent Initiatives: Recent initiatives include advancing Phase 2 clinical trials for BGE-175 and BGE-117, expanding its data platform, and pursuing strategic partnerships.
Summary
BioAge Labs is an innovative biotechnology company focused on developing therapies for aging-related diseases using a data-driven approach. The company's strengths lie in its proprietary data platform and clinical-stage assets. The company needs to be aware of the risks of clinical trial failures, competition, and regulatory hurdles. It's future depends on bringing successful clinical trials to market and building new partnerships.
Similar Companies
GOOGL
Alphabet Inc Class A
GOOGL
Alphabet Inc Class A
Sources and Disclaimers
Data Sources:
- Company website
- Press releases
- Industry reports
- Clinical trial data
- Venture capital databases
Disclaimers:
The information provided is based on publicly available data and should not be considered financial advice. Market share estimates are approximate and based on industry analysis and available data. Financial data is limited due to BioAge Labs' private status.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioAge Labs, Inc
Exchange NASDAQ | Headquaters Richmond, CA, United States | ||
IPO Launch date 2024-09-26 | Co-Founder, CEO, President, Treasurer, Secretary & Director Dr. Kristen Fortney Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 62 | Website https://bioagelabs.com |
Full time employees 62 | Website https://bioagelabs.com | ||
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.